Lenvatinib mesylate | E7080 | CAS#857890-39-2 | VEGFR2 inhibitor

MedKoo Cat#: 201080 | Name: Lenvatinib mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lenvatinib, also known as E7080, is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.

Chemical Structure

Lenvatinib mesylate

CAS#857890-39-2 (mesylate)

Theoretical Analysis

MedKoo Cat#: 201080

Name: Lenvatinib mesylate

CAS#: 857890-39-2 (mesylate)

Chemical Formula: C22H23ClN4O7S

Exact Mass: 0.0000

Molecular Weight: 522.96

Elemental Analysis: C, 50.53; H, 4.43; Cl, 6.78; N, 10.71; O, 21.42; S, 6.13

Price and Availability

Size	Price	Availability
25mg	USD 150.00	Ready to ship
50mg	USD 225.00	Ready to ship
100mg	USD 350.00	Ready to ship
200mg	USD 600.00	Ready to ship
500mg	USD 1,050.00	Ready to ship
1g	USD 1,650.00	Ready to ship
2g	USD 2,850.00	Ready to ship
5g	USD 5,750.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

857890-39-2 (mesylate) 417716-92-8 (free base)

Synonym

E7080; E-7080; E 7080; ER-203492-00; Lenvatinib; Lenvatinib mesylate; trade name Lenvima.

IUPAC/Chemical Name

4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide mesylate

InChi Key

HWLFIUUAYLEFCT-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

SMILES Code

O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.OS(=O)(C)=O

Appearance

White to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>5 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#BBC60217

View CoA: current batch, Lot#C8R04B25

QC Data

View QC data: current batch, Lot#BBC60217

View QC data: current batch, Lot#C8R04B25

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Lenvatinib mesylate (E7080 mesylate) is a tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET.

In vitro activity:

The antiproliferative activity of lenvatinib against nine HCC cell lines was examined in vitro. Lenvatinib showed selective and potent antiproliferative activity against the HCC cell lines Hep3B2.1‐7, HuH‐7, and JHH‐7, with IC50 values of 0.23, 0.42, and 0.64 μmol/L, respectively (Fig. 1A and B). Immunoblotting analysis showed that FGF19, FGFR4, and β‐Klotho were highly expressed in these three cell lines, indicating that the FGF19–FGFR4 axis was activated (Fig. 1C), consistent with previous reports. Lenvatinib also showed moderate inhibitory effects on the proliferation of SNU‐398, Li‐7, and HuH‐1 cells, with IC50 values of 1.56, 1.65, and 2.59 μmol/L, respectively (Fig. 1A and B). Although FGF19 protein was not expressed, some members of the FGFR family were detected in these cells (Fig. 1C). Because these cell lines are modestly sensitive to pan‐FGFR inhibitors such as BGJ398, lenvatinib might inhibit proliferation of the cells by targeting an activated FGF signaling pathway. Lenvatinib did not show clear antiproliferative activity against SK‐HEP‐1, SNU‐449, or PLC/PRF/5 cells (IC50 >5 μmol/L; Fig. 1A and B), which were also insensitive to pan‐FGFR inhibitors. Reference: Cancer Med. 2018 Jun;7(6):2641-2653. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010799/

In vivo activity:

The in vivo antitumor activity of lenvatinib against HCC (human hepatocellular carcinoma) xenografts with activated FGF signaling pathways in the Hep3B2.1‐7 and SNU‐398 models was evaluated. In vivo growth of xenograft tumors was significantly inhibited by lenvatinib at doses of 3–30 mg/kg in the Hep3B2.1‐7 model and 10, 30 mg/kg in the SNU‐398 model (Fig. 3A). BWL (body weight loss) of the treatment group was similar to that of the corresponding vehicle control group, although cachexia‐induced BWL was observed in each control group (Fig. S5). To examine whether lenvatinib inhibited FGF signaling pathways within the Hep3B2.1‐7 and SNU‐398 xenograft tumors, tumor samples were collected 2 h after a single lenvatinib treatment, and phosphorylation levels of FRS2 and another downstream molecule of FGFR, Erk1/2, were evaluated. Lenvatinib at 10 and 30 mg/kg inhibited phosphorylation of FRS2 and Erk1/2 in the Hep3B2.1‐7 model (Fig. 3C); lenvatinib at 3–30 mg/kg inhibited FRS2 phosphorylation in the SNU‐398 model (Fig. 3E); and lenvatinib at 30 mg/kg inhibited Erk1/2 phosphorylation in the SNU‐398 model (Fig. 3E). These results suggest that targeting FGFR of HCC cells underlies the antitumor activity of lenvatinib in preclinical HCC models with activated FGF signaling pathways. Reference: Cancer Med. 2018 Jun;7(6):2641-2653. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010799/

	Solvent	mg/mL	mM
Solubility
	DMSO	5.8	11.05
	DMSO:PBS (pH 7.2) (1:5)	0.2	0.31

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 522.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ogasawara S, Mihara Y, Kondo R, Kusano H, Akiba J, Yano H. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo. Anticancer Res. 2019 Nov;39(11):5973-5982. doi: 10.21873/anticanres.13802. PMID: 31704822. 2. Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018 Jun;7(6):2641-2653. doi: 10.1002/cam4.1517. Epub 2018 May 7. PMID: 29733511; PMCID: PMC6010799.

In vitro protocol:

In vivo protocol:

1: Tsukaguchi A, Ihara S, Yasuoka H, Minami S. Lenvatinib-refractory thymic mucinous carcinoma with PIK3CA mutation. Int Cancer Conf J. 2022 Aug 20;12(1):36-40. doi: 10.1007/s13691-022-00573-8. PMID: 36605843; PMCID: PMC9807735. 2: Sano S, Asahi Y, Kamiyama T, Kakisaka T, Orimo T, Nagatsu A, Aiyama T, Kazui K, Shomura H, Ueki S, Sakamoto Y, Shirakawa C, Kamachi H, Sugino H, Mitsuhashi T, Taketomi A. Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma. Int Cancer Conf J. 2022 Aug 17;12(1):7-13. doi: 10.1007/s13691-022-00567-6. PMID: 36605836; PMCID: PMC9807693. 3: Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y, Yabushita K, Motoyoshi K, Kudo M. Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan. Drugs Real World Outcomes. 2023 Jan 5. doi: 10.1007/s40801-022-00348-w. Epub ahead of print. PMID: 36602748. 4: Chen B, Zhang L, Cheng J, Wu T, Lei J, Yang X, Zhang R, Safadi R, Li Y, Si T, Lu Y. Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study. Drug Des Devel Ther. 2022 Dec 28;16:4429-4437. doi: 10.2147/DDDT.S386829. PMID: 36597443; PMCID: PMC9805705. 5: Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, Atsukawa M, Itobayashi E, Toyoda H, Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S. Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study. Liver Cancer. 2022 Jul 11;11(6):527-539. doi: 10.1159/000525145. PMID: 36589723; PMCID: PMC9801178. 6: Kim Y, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Goh MJ, Kang W, Kim SU. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2023 Feb 1;35(2):191-197. doi: 10.1097/MEG.0000000000002466. Epub 2022 Nov 1. PMID: 36574310. 7: Xie F, Chen B, Yang X, Wang H, Zhang G, Wang Y, Wang Y, Zhang N, Xue J, Long J, Li Y, Sun H, Xun Z, Liu K, Chen X, Song Y, Yang X, Lu Z, Mao Y, Sang X, Lu Y, Zhao H. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma. Front Immunol. 2022 Dec 9;13:1052937. doi: 10.3389/fimmu.2022.1052937. PMID: 36569829; PMCID: PMC9780480. 8: Denaro N, Garrone O, Ghidini M, Tomasello G, Hahne JC, Merlano MC, Locati LD. Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience. J Clin Med. 2022 Dec 9;11(24):7312. doi: 10.3390/jcm11247312. PMID: 36555928; PMCID: PMC9785927. 9: Dotinga M, Vriens D, van Velden FHP, Stam MK, Heemskerk JWT, Dibbets- Schneider P, Pool M, Rietbergen DDD, de Geus-Oei LF, Kapiteijn E. Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial. Diagnostics (Basel). 2022 Dec 14;12(12):3154. doi: 10.3390/diagnostics12123154. PMID: 36553163; PMCID: PMC9777156. 10: Mawatari S, Tamai T, Kumagai K, Saisyoji A, Muromachi K, Toyodome A, Taniyama O, Sakae H, Ijuin S, Tabu K, Oda K, Hiramine Y, Moriuchi A, Sakurai K, Kanmura S, Ido A. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma. Cancers (Basel). 2022 Dec 13;14(24):6139. doi: 10.3390/cancers14246139. PMID: 36551623; PMCID: PMC9776720. 11: Wang DZ, Li BH, Deng BL, Guo FQ, Hu SS, Yu NW, Liu J. Anti-CASPR2 encephalitis in a liver posttransplant patient receiving immune-suppression and lenvatinib: a case report and literature review. Neurol Sci. 2022 Dec 22. doi: 10.1007/s10072-022-06560-4. Epub ahead of print. PMID: 36547776. 12: Utsunomiya T, Sakamoto K, Iwata M, Ito C, Sakamoto A, Matsui T, Shine M, Nishi Y, Uraoka M, Nagaoka T, Tamura K, Funamizu N, Ogawa K, Kitazawa R, Takada Y. [A Case of Unresectable Hepatocellular Carcinoma Treated using Lenvatinib and Conversion Surgery]. Gan To Kagaku Ryoho. 2022 Dec;49(12):1365-1367. Japanese. PMID: 36539251. 13: Kimura M, Asano H, Usami E, Teramachi H, Yoshimura T. Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma. J Oncol Pharm Pract. 2022 Dec 19:10781552221145475. doi: 10.1177/10781552221145475. Epub ahead of print. PMID: 36537044. 14: Zhu Y, Liu K, Ding D, Peng L. First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States- Based Cost-Effectiveness Analysis. Clin Genitourin Cancer. 2022 Nov 25:S1558-7673(22)00248-8. doi: 10.1016/j.clgc.2022.11.014. Epub ahead of print. PMID: 36529626. 15: Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2022 Nov 25;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub ahead of print. PMID: 36527976. 16: Deng Y, Yang J, Chen Y, Wang J, Fu B, Zhang T, Yi S, Yang Y. Development of a Risk Classifier to Predict Tumor Recurrence and Lenvatinib Benefits in Hepatocellular Carcinoma After Liver Transplantation. Transplant Proc. 2022 Dec 13:S0041-1345(22)00770-9. doi: 10.1016/j.transproceed.2022.11.002. Epub ahead of print. PMID: 36522222. 17: Yuan P, Song J, Wang F, Zhu G, Chen B. Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma. Invest New Drugs. 2022 Dec 13. doi: 10.1007/s10637-022-01323-6. Epub ahead of print. Erratum for: Invest New Drugs. 2022 Oct;40(5):1125-1132. PMID: 36513875. 18: Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. J Cancer Res Clin Oncol. 2022 Dec 13. doi: 10.1007/s00432-022-04512-1. Epub ahead of print. PMID: 36509984. 19: Li G, Shu B, Zheng Z, Yin H, Zhang C, Xiao Y, Yang Y, Yan Z, Zhang X, Yang S, Li G, Dong J. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi- center phase I trial. Front Oncol. 2022 Nov 24;12:1051916. doi: 10.3389/fonc.2022.1051916. PMID: 36505833; PMCID: PMC9730694. 20: Yi Y, Sun BY, Weng JL, Zhou C, Zhou CH, Cai MH, Zhang JY, Gao H, Sun J, Zhou J, Fan J, Ren N, Qiu SJ. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study. Front Oncol. 2022 Nov 24;12:1046584. doi: 10.3389/fonc.2022.1046584. PMID: 36505772; PMCID: PMC9731103.